IPHA vs JSPR

Innate Pharma S.A. vs Jasper Therapeutics, Inc. — Valuation Comparison 2026

IPHA

Biological Products, (No Diagnostic Substances)
Innate Pharma S.A.
Quality
4.8
out of 10
Value Trap
26
LOW
Price
$1.83
Last close
Models
8/13
Active
VS

JSPR

Biological Products, (No Diagnostic Substances)
Jasper Therapeutics, Inc.
Quality
3.5
out of 10
Value Trap
36
LOW
Price
$0.83
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType IPHA Fair ValueIPHA Upside JSPR Fair ValueJSPR Upside
Bayesian DCF Intrinsic $0.62 -66.1% $0.48 -42.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.87 -52.3% $2.18 +163.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IPHA vs JSPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IPHA vs JSPR — Which Stock Is More Undervalued?

IPHA scores higher with a 4.8/10 quality rating vs JSPR's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Innate Pharma S.A. (IPHA) and Jasper Therapeutics, Inc. (JSPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IPHA currently trades at $1.83 with a QOC of 4.8/10, while JSPR trades at $0.83 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).